Elise G Valdés1, Melissa L O'Connor2, Ergun Y Uc3,4, Robert A Hauser5, Ross Andel1,6, Jerri D Edwards1. 1. a School of Aging Studies University of South Florida , Tampa , FL , USA. 2. b Department of Human Development and Family Science , North Dakota State University , Fargo , ND , USA. 3. c Department of Neurology , University of Iowa , Iowa City , IA , USA. 4. d Neurology Service , Veterans Affairs Medical Center , Iowa City , IA , USA. 5. e Department of Neurology , University of South Florida , Tampa , FL , USA. 6. f International Clinical Research Center , St. Anne's University Hospital , Brno , Czech Republic.
Abstract
INTRODUCTION: Recent research indicated that cognitive speed of processing training (SPT) improved Useful Field of View (UFOV) among individuals with Parkinson's disease (PD). The effects of SPT in PD have not been further examined. The objectives of the current study were to investigate use, maintenance and dose effects of SPT among individuals with PD. METHODS: Participants who were randomized to SPT or a delayed control group completed the UFOV at a six-month follow-up visit. Use of SPT was monitored across the six-month study period. Regression explored factors affecting SPT use. Mixed effect models were conducted to examine the durability of training gains among those randomized to SPT (n = 44), and training dose effects among the entire sample (n = 87). RESULTS: The majority of participants chose to continue to use SPT (52%). Those randomized to SPT maintained improvements in UFOV performance. A significant dose effect of SPT was evident such that more hours of training were associated with greater UFOV performance improvements. The cognitive benefits derived from SPT in PD may be maintained for up to three months. CONCLUSION: Future research should determine how long gains endure and explore if such training gains transfer.
RCT Entities:
INTRODUCTION: Recent research indicated that cognitive speed of processing training (SPT) improved Useful Field of View (UFOV) among individuals with Parkinson's disease (PD). The effects of SPT in PD have not been further examined. The objectives of the current study were to investigate use, maintenance and dose effects of SPT among individuals with PD. METHODS:Participants who were randomized to SPT or a delayed control group completed the UFOV at a six-month follow-up visit. Use of SPT was monitored across the six-month study period. Regression explored factors affecting SPT use. Mixed effect models were conducted to examine the durability of training gains among those randomized to SPT (n = 44), and training dose effects among the entire sample (n = 87). RESULTS: The majority of participants chose to continue to use SPT (52%). Those randomized to SPT maintained improvements in UFOV performance. A significant dose effect of SPT was evident such that more hours of training were associated with greater UFOV performance improvements. The cognitive benefits derived from SPT in PD may be maintained for up to three months. CONCLUSION: Future research should determine how long gains endure and explore if such training gains transfer.
Authors: Jerri D Edwards; Charlsie Myers; Lesley A Ross; Daniel L Roenker; Gayla M Cissell; Alexis M McLaughlin; Karlene K Ball Journal: Gerontologist Date: 2009-06-02
Authors: George W Rebok; Karlene Ball; Lin T Guey; Richard N Jones; Hae-Young Kim; Jonathan W King; Michael Marsiske; John N Morris; Sharon L Tennstedt; Frederick W Unverzagt; Sherry L Willis Journal: J Am Geriatr Soc Date: 2014-01-13 Impact factor: 5.562
Authors: Anna Prats París; Heidi Guerra Saleta; Maria de la Cruz Crespo Maraver; Emmanuel Silvestre; Maite Garolera Freixa; Cristina Petit Torrellas; Silvia Alonso Pont; Marc Fabra Nadal; Sheila Alcaine Garcia; Maria Victoria Perea Bartolomé; Valentina Ladera Fernández; Angels Rusiñol Bayés Journal: Mov Disord Date: 2011-03-25 Impact factor: 10.338
Authors: Karlene Ball; Daniel B Berch; Karin F Helmers; Jared B Jobe; Mary D Leveck; Michael Marsiske; John N Morris; George W Rebok; David M Smith; Sharon L Tennstedt; Frederick W Unverzagt; Sherry L Willis Journal: JAMA Date: 2002-11-13 Impact factor: 56.272
Authors: Murray Grossman; Edgar Zurif; Christine Lee; Penny Prather; Julia Kalmanson; Matthew B Stern; Howard I Hurtig Journal: Neuropsychology Date: 2002-04 Impact factor: 3.295
Authors: Isabella H K Leung; Courtney C Walton; Harry Hallock; Simon J G Lewis; Michael Valenzuela; Amit Lampit Journal: Neurology Date: 2015-10-30 Impact factor: 9.910
Authors: Vasiliki Orgeta; Kathryn R McDonald; Ellen Poliakoff; John Vincent Hindle; Linda Clare; Iracema Leroi Journal: Cochrane Database Syst Rev Date: 2020-02-26